Diagnose und Therapie der angeborenen milden Thrombozytenfunktionsstörung: Ein Bericht über 14 Patienten

  • H. Knecht
  • Ph. Schneider
  • F. Bachmann
Conference paper

Zusammenfassung

Angeborene milde Thrombozytenfunktionsstörungen sind häufiger als allgemein angenommen und differentialdiagnostisch gegenüber der milden Form der von Willebrand ’ schen Erkrankung abzugrenzen [1]. Eine frühzeitige Diagnosestellung ist wünschenswert, da durch Verabreichung von DDAVP (l-deamino-8-D- arginin Vasopressin) vor chirurgischen Wahleingriffen eine Normalisierung der primären Hämostase erreicht werden kann [2].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bachmann F (1980) Diagnostic approach to mild bleeding disorders. Semin Hematol 17:292–305PubMedGoogle Scholar
  2. 2.
    Kobrinsky NL, Israels ED, Gerrard JM, Cheang MS, Watson CM, Bishop AJ, Schroeder ML (1984) Shortening of bleeding time by l-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet i:1145–1148CrossRefGoogle Scholar
  3. 3.
    Hardisty RM, McPherson JC (1962) A one stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thrombosis et Diathesis Haemorrhagica 7:215–229PubMedGoogle Scholar
  4. 4.
    Ruggeri ZM, Zimmermann TS (1980) The complex multimeric composition of factor Vlll/von Willebrand factor. Blood 57:1140–1143Google Scholar
  5. 5.
    Nieuwenhuis HK, Akkerman JWM, Sixma JJ (1987) Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood 70:620–623PubMedGoogle Scholar
  6. 6.
    DiMichele DM, Hathaway WE (1990) Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 33:39–45CrossRefGoogle Scholar
  7. 7.
    Mannucci PM (1986) Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost 8:19–45Google Scholar
  8. 8.
    Sakariassen KS, Cattaneo M, van den Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ (1984) DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 64:229–236PubMedGoogle Scholar
  9. 9.
    Zwaginga JJ, Ijsseldjik MJW, Beeser-Visser N, de Groot PG, Vos J, Sixma JJ (1990) High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 75:1498–1508PubMedGoogle Scholar
  10. 10.
    Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG (1990) Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb: Ilia are involved in platelet adhesion to fibrin in flowing whole blood. Blood 76:345–353PubMedGoogle Scholar
  11. 11.
    Tsai HM, Sussmann II, Nagel RL, Kaul DK (1990) Desmopressin induces adhesion of normal human erythrocytes to the endothelial surface of a perfused microvascular preparation. Blood 75:261–265PubMedGoogle Scholar
  12. 12.
    Cattaneo M, Moia M, Delia Valle P, Castellana P, Mannucci PM (1989) DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Wille- brand factor. Blood 74:1972–1975PubMedGoogle Scholar
  13. 13.
    Smith TJ, Gill JC, Ambruso DR, Hathaway WE (1989) Hyponatremia and seizures in young children given DDAVP. Am J Hematol 31:199–202PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. Knecht
    • 1
  • Ph. Schneider
    • 1
  • F. Bachmann
    • 1
  1. 1.LausanneSchweiz

Personalised recommendations